Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: An endocrine society clinical practice guideline

Anne L. Peters, Andrew J. Ahmann, Tadej Battelino, Alison Evert, Irl B. Hirsch, Mohammad H Murad, William E. Winter, Howard Wolpert

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Objective: To formulate clinical practice guidelines for the use of continuous glucose monitoring and continuous subcutaneous insulin infusion in adults with diabetes. Participants: The participants include an Endocrine Society-appointed Task Force of seven experts, a methodologist, anda medical writer. The American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology co-sponsored this guideline. Evidence: The Task Force developed this evidence-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned one systematic review and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Continuous subcutaneous insulin infusion and continuous glucose monitoring have an important role in the treatment of diabetes. Data from randomized controlled trials are limited onthe use of medical devices, but existing studies support the use of diabetes technology for a wide variety of indications. This guideline presents a review of the literature and practice recommendations for appropriate device use. (J Clin Endocrinol Metab 101: 3922-3937, 2016).

Original languageEnglish (US)
Pages (from-to)3922-3937
Number of pages16
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Subcutaneous Infusions
Medical problems
Practice Guidelines
Advisory Committees
Guidelines
Insulin
Technology
Glucose
Monitoring
Consensus
Committee Membership
Equipment and Supplies
Group Processes
Postal Service
Teleconferencing
Therapeutics
Randomized Controlled Trials
Communication

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults : An endocrine society clinical practice guideline. / Peters, Anne L.; Ahmann, Andrew J.; Battelino, Tadej; Evert, Alison; Hirsch, Irl B.; Murad, Mohammad H; Winter, William E.; Wolpert, Howard.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 101, No. 11, 01.11.2016, p. 3922-3937.

Research output: Contribution to journalReview article

Peters, Anne L. ; Ahmann, Andrew J. ; Battelino, Tadej ; Evert, Alison ; Hirsch, Irl B. ; Murad, Mohammad H ; Winter, William E. ; Wolpert, Howard. / Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults : An endocrine society clinical practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2016 ; Vol. 101, No. 11. pp. 3922-3937.
@article{a120715acdd546a1b28da370ccfb0b80,
title = "Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: An endocrine society clinical practice guideline",
abstract = "Objective: To formulate clinical practice guidelines for the use of continuous glucose monitoring and continuous subcutaneous insulin infusion in adults with diabetes. Participants: The participants include an Endocrine Society-appointed Task Force of seven experts, a methodologist, anda medical writer. The American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology co-sponsored this guideline. Evidence: The Task Force developed this evidence-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned one systematic review and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Continuous subcutaneous insulin infusion and continuous glucose monitoring have an important role in the treatment of diabetes. Data from randomized controlled trials are limited onthe use of medical devices, but existing studies support the use of diabetes technology for a wide variety of indications. This guideline presents a review of the literature and practice recommendations for appropriate device use. (J Clin Endocrinol Metab 101: 3922-3937, 2016).",
author = "Peters, {Anne L.} and Ahmann, {Andrew J.} and Tadej Battelino and Alison Evert and Hirsch, {Irl B.} and Murad, {Mohammad H} and Winter, {William E.} and Howard Wolpert",
year = "2016",
month = "11",
day = "1",
doi = "10.1210/jc.2016-2534",
language = "English (US)",
volume = "101",
pages = "3922--3937",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults

T2 - An endocrine society clinical practice guideline

AU - Peters, Anne L.

AU - Ahmann, Andrew J.

AU - Battelino, Tadej

AU - Evert, Alison

AU - Hirsch, Irl B.

AU - Murad, Mohammad H

AU - Winter, William E.

AU - Wolpert, Howard

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective: To formulate clinical practice guidelines for the use of continuous glucose monitoring and continuous subcutaneous insulin infusion in adults with diabetes. Participants: The participants include an Endocrine Society-appointed Task Force of seven experts, a methodologist, anda medical writer. The American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology co-sponsored this guideline. Evidence: The Task Force developed this evidence-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned one systematic review and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Continuous subcutaneous insulin infusion and continuous glucose monitoring have an important role in the treatment of diabetes. Data from randomized controlled trials are limited onthe use of medical devices, but existing studies support the use of diabetes technology for a wide variety of indications. This guideline presents a review of the literature and practice recommendations for appropriate device use. (J Clin Endocrinol Metab 101: 3922-3937, 2016).

AB - Objective: To formulate clinical practice guidelines for the use of continuous glucose monitoring and continuous subcutaneous insulin infusion in adults with diabetes. Participants: The participants include an Endocrine Society-appointed Task Force of seven experts, a methodologist, anda medical writer. The American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology co-sponsored this guideline. Evidence: The Task Force developed this evidence-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned one systematic review and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the American Association for Clinical Chemistry, the American Association of Diabetes Educators, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Conclusions: Continuous subcutaneous insulin infusion and continuous glucose monitoring have an important role in the treatment of diabetes. Data from randomized controlled trials are limited onthe use of medical devices, but existing studies support the use of diabetes technology for a wide variety of indications. This guideline presents a review of the literature and practice recommendations for appropriate device use. (J Clin Endocrinol Metab 101: 3922-3937, 2016).

UR - http://www.scopus.com/inward/record.url?scp=84994884983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994884983&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-2534

DO - 10.1210/jc.2016-2534

M3 - Review article

C2 - 27588440

AN - SCOPUS:84994884983

VL - 101

SP - 3922

EP - 3937

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -